Episode
Enliven Therapeutics Stock Move & Outlook
- Published
- Jun 27, 2026
- Duration seconds
- 119
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/enliven-therapeutics-stock-move-outlook/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/enliven-therapeutics-stock-move-outlook.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Orbimed Advisors cashed out nearly $39 million by selling 860,000 shares of Enliven Therapeutics, still holding over 6.5 million shares — a move that didn’t hurt the stock, which jumped to $50 after the sale. With a 130% one-year surge, Enliven continues its promising path in cancer drug development, advancing key candidates in early trials for chronic myeloid leukemia and HER2-mutant cancers. Positive clinical data and a strong cash reserve from a recent IPO keep investors optimistic, suggesting Orbimed’s exit may signal confidence in Enliven’s long-term potential. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/7f6898c447d95db6